Cargando…

Hema-seq reveals genomic aberrations in a rare simultaneous occurrence of hematological malignancies

Co-occurrence of multiple myeloma and acute myelogenous leukemia is rare, with both malignancies often tracing back to multipotent hematopoietic stem cells. Cytogenetic techniques are the established baseline for diagnosis and characterization of complex hematological malignancies. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Dajeong, Lee, Amos C., Shin, Kyoungseob, Kim, Jinhyun, Ham, Myoung Hee, Lee, Changhee, Lee, Sumin, Choi, Ahyoun, Ryu, Taehoon, Kim, Okju, Jung, Yushin, Kwon, Sunghoon, Lee, Dong Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626221/
https://www.ncbi.nlm.nih.gov/pubmed/37852254
http://dx.doi.org/10.1016/j.crmeth.2023.100617
Descripción
Sumario:Co-occurrence of multiple myeloma and acute myelogenous leukemia is rare, with both malignancies often tracing back to multipotent hematopoietic stem cells. Cytogenetic techniques are the established baseline for diagnosis and characterization of complex hematological malignancies. In this study, we develop a workflow called Hema-seq to delineate clonal changes across various hematopoietic lineages through the integration of whole-genome sequencing, copy-number variations, cell morphology, and cytogenetic aberrations. In Hema-seq, cells are selected from Wright-stained slides and fluorescent probe-stained slides for sequencing. This technique therefore enables direct linking of whole-genome sequences to cytogenetic profiles. Through this method, we mapped sequential clonal alterations within the hematopoietic lineage, identifying critical shifts leading to myeloma and acute myeloid leukemia (AML) cell formations. By synthesizing data from each cell lineage, we provided insights into the hematopoietic tree’s clonal evolution. Overall, this study highlights Hema-seq’s capability in deciphering genomic heterogeneity in complex hematological malignancies, which can enable better diagnosis and treatment strategies.